title: Manidipine-delapril combination in the management of hypertension.
abstract: High blood pressure (BP) is the major cardiovascular risk factor and the main cause of death around the world. Control of blood pressure reduces the high mortality associated with hypertension and the most recent guidelines recommend reducing arterial BP values below 140/90 mmHg for all hypertensive patients (130/80 in diabetics) as a necessary step to reduce global cardiovascular risk, which is the fundamental objective of the treatment. To achieve these target BP goals frequently requires combination therapy with two or more antihypertensive agents. Although the combination of a diuretic and an angiotensin converting enzyme inhibitor (ACEI) is the most commonly used in the clinical practice, the combination of an ACEI and a calcium channel blocker may have an additive antihypertensive effect, a favorable effect on the metabolic profile, and an increased target organ damage protection. The new oral fixed combination manidipine 10 mg/delapril 30 mg has a greater antihypertensive effect than both components of the combination separately, and in non-responders to monotherapy with manidipine or delapril the average reduction of systolic and diastolic BP is 16/10 mmHg. The combination is well tolerated and the observed adverse effects are of the same nature as those observed in patients treated with the components as monotherapy. However, combination therapy reduces the incidence of ankle edema in patients treated with manidipine.
authors: Hypertension Unit, Hospital Clinico San Carlos, Complutense University, Madrid, Spain. mluqueo@telefonica.net
authors: Manuel Luque
authors: ML
authors: Otero
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D004095:Dihydropyridines / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007189:Indans / Q000494:pharmacology* / Q000627:therapeutic use; D009578:Nitrobenzenes; D010879:Piperazines
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D007189:Indans; D009578:Nitrobenzenes; D010879:Piperazines; C054218:manidipine; C047759:delapril
references: J Cardiovasc Pharmacol. 2000 Jun;35(6):926-31
references: 10836728
references: J Hypertens. 2000 Dec;18(12):1871-5
references: 11132613
references: Hypertension. 2001 Mar;37(3):943-8
references: 11244022
references: Ann Intern Med. 2001 Jul 17;135(2):73-87
references: 11453706
references: J Cardiovasc Pharmacol. 2001 Oct;38(4):642-50
references: 11588535
references: J Hypertens. 2002 Feb;20(2):159-69
references: 11821696
references: J Hypertens. 2002 Aug;20(8):1461-4
references: 12172300
references: J Renin Angiotensin Aldosterone Syst. 2002 Jun;3(2):79-89
references: 12228847
references: Circulation. 2002 Nov 5;106(19):2422-7
references: 12417537
references: JAMA. 2002 Dec 18;288(23):2981-97
references: 12479763
references: Lancet. 2002 Dec 14;360(9349):1903-13
references: 12493255
references: JAMA. 2003 May 14;289(18):2363-9
references: 12746359
references: JAMA. 2003 May 21;289(19):2560-72
references: 12748199
references: J Hypertens. 2003 Jun;21(6):1011-53
references: 12777938
references: J Cardiovasc Pharmacol. 1992 Dec;20(6):895-9
references: 1282591
references: BMJ. 2003 Jun 28;326(7404):1427
references: 12829555
references: Am J Med. 2003 Jul;115(1):41-6
references: 12867233
references: Arzneimittelforschung. 2003;53(9):627-34
references: 14558436
references: Lancet. 2003 Nov 8;362(9395):1527-35
references: 14615107
references: J Hum Hypertens. 2004 Oct;18(10):687-91
references: 15071488
references: J Hypertens. 2004 Mar;22(3):479-86
references: 15076152
references: J Hypertens. 2004 Jan;22(1):51-7
references: 15106794
references: Hypertension. 2004 Jun;43(6):1338-44
references: 15117908
references: Lancet. 2004 Jun 19;363(9426):2022-31
references: 15207952
references: Drugs. 2004;64(17):1923-40
references: 15329044
references: N Engl J Med. 2004 Nov 4;351(19):1941-51
references: 15516697
references: Clin Ther. 2004 Sep;26(9):1419-26
references: 15531004
references: J Cardiovasc Pharmacol. 2005 Mar;45(3):241-6
references: 15725949
references: Clin Ther. 2005 Feb;27(2):166-73
references: 15811479
references: Arch Intern Med. 2005 Jun 27;165(12):1410-9
references: 15983291
references: Eur J Clin Pharmacol. 2005 Aug;61(7):483-90
references: 16021438
references: Blood Press Suppl. 2005 Jul;1:6-13
references: 16060411
references: Lancet. 2005 Sep 10-16;366(9489):895-906
references: 16154016
references: J Hypertens. 2006 Jan;24(1):3-10
references: 16331092
references: Drugs. 2005;65 Suppl 2:21-7
references: 16398059
references: Lancet. 2006 May 27;367(9524):1747-57
references: 16731270
references: Am J Hypertens. 1991 Jan;4(1 Pt 2):23S-28S
references: 2009144
references: J Cardiovasc Pharmacol. 1987;10 Suppl 10:S147-8
references: 2455119
references: Curr Ther Res Clin Exp. 2003 Jul;64(7):422-33
references: 24944393
references: Clin Pharmacol Ther. 1988 Mar;43(3):242-9
references: 3345615
references: J Pharmacol Exp Ther. 1987 Nov;243(2):703-10
references: 3681701
references: JAMA. 1970 Aug 17;213(7):1143-52
references: 4914579
references: J Clin Invest. 1995 Aug;96(2):793-800
references: 7635974
references: J Hum Hypertens. 1994 Feb;8(2):145-9
references: 8207741
references: Hypertension. 1994 Jan;23(1):83-91
references: 8282334
references: N Engl J Med. 1993 Nov 11;329(20):1456-62
references: 8413456
references: J Diabetes Complications. 1995 Oct-Dec;9(4):215-9
references: 8573730
references: Hypertens Res. 1996 Mar;19(1):31-6
references: 8829821
references: J Hypertens. 1995 Dec;13(12 Pt 1):1363-75
references: 8866898
references: Diabetes Res Clin Pract. 1996 Jun;33(1):43-51
references: 8877275
references: Blood Press Suppl. 1996;5:16-23
references: 8973788
references: J Hypertens. 1996 Sep;14(9):1139-46
references: 8986916
references: J Hypertens Suppl. 1997 Mar;15(2):S39-42
references: 9218197
references: Clin Ther. 1997;19 Suppl A:3-17
references: 9385501
references: Kidney Int. 1998 Jun;53(6):1559-73
references: 9607186
references: Lancet. 1998 Jun 13;351(9118):1755-62
references: 9635947
references: J Hypertens. 1998 Nov;16(11):1667-76
references: 9856368
references: J Hypertens. 1998 Dec;16(12 Pt 1):1823-9
references: 9869017
references: N Engl J Med. 1998 Dec 31;339(27):1957-63
references: 9869666